Stabilization challenges and formulation strategies associated with oral biologic drug delivery systems.
Delivery of proteins to mucosal tissues of GI tract typically utilize formulations which protect against proteolysis and target the mucosal tissues. Using case studies from literature and the authors' own work, the in-process stability and solid state storage stability of biopharmaceuticals formulated in delivery systems designed for oral delivery to the GI tract will be reviewed. Among the range of delivery systems, biodegradable polymer systems for protection and controlled release of proteins have been the most studied; hence these systems will be covered in greater depth. These delivery systems include polymeric biodegradable microspheres or nanospheres that contain proteins or vaccines, which are designed to reduce the number of administrations/inoculations and the total protein dose required to achieve the desired biological effect. Specifically, this review will include a landscape survey of the systems that have been studied, the manufacturing processes involved, stability through the manufacturing process, key pharmaceutical formulation parameters that impact stability of the encased proteins, and storage stability of the encapsulated proteins in these delivery systems.
Vu
V
Truong-Le
Phillip M
PM
Lovalenti
Ahmad M
AM
Abdul-Fattah
D000284:Administration, Oral; D000818:Animals; D002626:Chemistry, Pharmaceutical / Q000379:methods; D016503:Drug Delivery Systems; D015195:Drug Design; D004356:Drug Storage; D006801:Humans; D008863:Microspheres; D054118:Nanospheres; D011108:Polymers / Q000737:chemistry; D055550:Protein Stability; D011506:Proteins / Q000008:administration & dosage* / Q000737:chemistry
D011108:Polymers; D011506:Proteins
Excipients; Formulation; Microparticles; Oral drug delivery; Peptides; Proteins; Stabilization; Vaccines